• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三阴性乳腺癌与马来西亚女性的表皮生长因子受体(EGFR)、细胞角蛋白5/6(CK5/6)和原癌基因c-KIT表达有关。

Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women.

作者信息

Kanapathy Pillai Shant Kishen, Tay Annie, Nair Suseela, Leong Chee-Onn

机构信息

School of Pharmacy and Health Sciences, International Medical University, Bukit Jalil, Kuala Lumpur, 57000, Malaysia.

出版信息

BMC Clin Pathol. 2012 Sep 26;12:18. doi: 10.1186/1472-6890-12-18.

DOI:10.1186/1472-6890-12-18
PMID:23009686
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3582471/
Abstract

BACKGROUND

Triple-negative breast cancer (TNBC) is a heterogeneous subgroup of breast cancer characterized by the lack of estrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2) expressions. This subgroup of refractory disease tends to have aggressive clinical behavior, high frequency of metastasis and lack of response to current hormonal or targeted therapies. Despite numerous studies reporting the clinicopathological features of TNBC and its association with the basal-like phenotype in the Western population, only limited data are available in the Asian population. Therefore, the aim of this study was to investigate the clinicopathological characteristics of TNBC and its association with epidermal growth factor receptor (EGFR), cytokeratin 5/6 (CK5/6) and mast/stem cell growth factor receptor (c-KIT or CD117) expression in Malaysian women.

METHODS

A total of 340 patients diagnosed with primary breast cancer between 2002 and 2006 in Malaysia were reviewed and analyzed.

RESULTS

The incidence of TNBC was 12.4% (42/340). Bivariate analysis revealed that TNBC was strongly associated with a younger age, higher grade tumor and p53 expression. Further immunohistochemical analysis suggested that TNBC in Malaysian women was strongly associated with EGFR, CK5/6 and c-KIT expression with high a Ki-67 proliferation index.

CONCLUSION

In conclusion, our study confirms the association of TNBC with basal-like marker expression (EGFR, CK5/6 and c-KIT) in Malaysian women, consistent with studies in other populations.

摘要

背景

三阴性乳腺癌(TNBC)是乳腺癌的一个异质性亚组,其特征是缺乏雌激素受体(ER)、孕激素受体(PR)以及人表皮生长因子受体2(HER2)表达。这一难治性疾病亚组往往具有侵袭性临床行为、高转移频率且对当前激素或靶向治疗无反应。尽管有大量研究报道了西方人群中TNBC的临床病理特征及其与基底样表型的关联,但亚洲人群中的相关数据有限。因此,本研究旨在调查马来西亚女性中TNBC的临床病理特征及其与表皮生长因子受体(EGFR)、细胞角蛋白5/6(CK5/6)和肥大/干细胞生长因子受体(c-KIT或CD117)表达的关联。

方法

对2002年至2006年间在马来西亚诊断为原发性乳腺癌的340例患者进行回顾性分析。

结果

TNBC的发病率为12.4%(42/340)。双变量分析显示,TNBC与年轻、高分级肿瘤和p53表达密切相关。进一步的免疫组化分析表明,马来西亚女性的TNBC与EGFR、CK5/6和c-KIT表达密切相关,Ki-67增殖指数较高。

结论

总之,我们的研究证实了马来西亚女性中TNBC与基底样标志物表达(EGFR、CK5/6和c-KIT)的关联,这与其他人群的研究结果一致。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519e/3582471/ad58e3e036b7/1472-6890-12-18-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519e/3582471/2cfb2acb18e1/1472-6890-12-18-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519e/3582471/ad58e3e036b7/1472-6890-12-18-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519e/3582471/2cfb2acb18e1/1472-6890-12-18-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519e/3582471/ad58e3e036b7/1472-6890-12-18-2.jpg

相似文献

1
Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women.三阴性乳腺癌与马来西亚女性的表皮生长因子受体(EGFR)、细胞角蛋白5/6(CK5/6)和原癌基因c-KIT表达有关。
BMC Clin Pathol. 2012 Sep 26;12:18. doi: 10.1186/1472-6890-12-18.
2
Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.细胞角蛋白5/6、雄激素受体和p53的免疫组化共表达状态作为三阴性乳腺癌辅助化疗的预后因素
Med Mol Morphol. 2016 Mar;49(1):11-21. doi: 10.1007/s00795-015-0109-0. Epub 2015 May 26.
3
Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.使用组合生物标志物对三阴性乳腺癌患者的预后进行分层
PLoS One. 2016 Mar 1;11(3):e0149661. doi: 10.1371/journal.pone.0149661. eCollection 2016.
4
Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.雄激素受体表达缺失导致基底样表型的出现,并且是非转移性三阴性乳腺癌临床预后不良的一个预测指标。
Front Oncol. 2020 Jul 28;10:1083. doi: 10.3389/fonc.2020.01083. eCollection 2020.
5
Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.表皮生长因子受体(EGFR)和细胞角蛋白5/6免疫组化表达在三阴性乳腺癌中的预后影响
Ann Diagn Pathol. 2017 Jun;28:43-53. doi: 10.1016/j.anndiagpath.2017.01.009. Epub 2017 Feb 4.
6
Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification.乳腺癌分类中p53与表皮生长因子受体表达之间的相关性
Genet Mol Res. 2015 Apr 28;14(2):4282-90. doi: 10.4238/2015.April.28.10.
7
Clinico-Pathological Characteristics of Triple Negative and Non Triple Negative High Grade Breast Carcinomas with and Without Basal Marker (CK5/6 and EGFR) Expression at a Rural Tertiary Hospital in India.印度一家农村三级医院中具有和不具有基底标志物(CK5/6和EGFR)表达的三阴性和非三阴性高级别乳腺癌的临床病理特征
Breast Cancer (Auckl). 2012;6:21-9. doi: 10.4137/BCBCR.S8611. Epub 2012 Jan 9.
8
Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.从三阴性乳腺癌和 35 岁以下女性的组织微阵列中,通过差异标记物表达推断乳腺癌的基底上皮表型。
Breast J. 2012 Sep;18(5):399-405. doi: 10.1111/j.1524-4741.2012.01279.x. Epub 2012 Aug 10.
9
c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.基底样和非基底样三阴性乳腺癌中c-Met和ERβ的表达差异
Tumour Biol. 2016 Aug;37(8):11385-95. doi: 10.1007/s13277-016-5010-5. Epub 2016 Mar 11.
10
Correlation of CK5 and EGFR with Clinicopathological Profile of Triple-Negative Breast Cancer.CK5和EGFR与三阴性乳腺癌临床病理特征的相关性
Patholog Res Int. 2014;2014:141864. doi: 10.1155/2014/141864. Epub 2014 Oct 23.

引用本文的文献

1
Extracellular Vesicles in Triple-Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential.三阴性乳腺癌中的细胞外囊泡:免疫调节、生物标志物及免疫治疗潜力
Cancers (Basel). 2023 Oct 7;15(19):4879. doi: 10.3390/cancers15194879.
2
Sialyl Lewis and Cytokeratin Crosstalk in Triple Negative Breast Cancer.三阴性乳腺癌中唾液酸 Lewis 与细胞角蛋白的相互作用
Cancers (Basel). 2023 Jan 25;15(3):731. doi: 10.3390/cancers15030731.
3
New C3H Kit cancer mouse model develops late-onset malignant mammary tumors with high penetrance.

本文引用的文献

1
An analysis of predictive biomarkers in routine histopathological reporting of infiltrating ductal breast carcinoma in a tertiary hospital in Malaysia with a focus on limitations and directions for future development.马来西亚一家三级医院浸润性导管癌常规组织病理学报告中的预测生物标志物分析,重点关注局限性和未来发展方向。
Malays J Pathol. 2011 Jun;33(1):35-42.
2
Triple-negative and basal-like breast cancer: implications for oncologists.三阴性和基底样乳腺癌:对肿瘤学家的启示
Curr Oncol. 2011 Aug;18(4):161-4. doi: 10.3747/co.v18i4.824.
3
Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.
新型 C3H Kit 癌症小鼠模型可发展出具有高外显率的迟发性恶性乳腺肿瘤。
Sci Rep. 2022 Nov 17;12(1):19793. doi: 10.1038/s41598-022-23218-5.
4
c-Kit Induces Migration of Triple-Negative Breast Cancer Cells and Is a Promising Target for Tyrosine Kinase Inhibitor Treatment.c-Kit 诱导三阴性乳腺癌细胞迁移,是酪氨酸激酶抑制剂治疗的有前途的靶点。
Int J Mol Sci. 2022 Aug 5;23(15):8702. doi: 10.3390/ijms23158702.
5
Down Regulated Expression Levels of miR-27b and miR-451a as a Potential Biomarker for Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy.miR-27b 和 miR-451a 的下调表达水平可作为接受 TAC 化疗的三阴性乳腺癌患者的潜在生物标志物。
Asian Pac J Cancer Prev. 2022 Mar 1;23(3):1053-1059. doi: 10.31557/APJCP.2022.23.3.1053.
6
Regulation of Cellular and Cancer Stem Cell-Related Putative Gene Expression of Parental and CD44CD24 Sorted MDA-MB-231 Cells by Cisplatin.顺铂对亲本及CD44CD24分选的MDA-MB-231细胞中细胞及癌症干细胞相关假定基因表达的调控
Pharmaceuticals (Basel). 2021 Apr 21;14(5):391. doi: 10.3390/ph14050391.
7
Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities.三阴性乳腺癌:现有和未来诊断方式的综述。
Medicina (Kaunas). 2021 Jan 12;57(1):62. doi: 10.3390/medicina57010062.
8
Clinicopathological and Prognostic Characteristics of Malaysian Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy Regimen.接受TAC化疗方案的马来西亚三阴性乳腺癌患者的临床病理特征及预后特征
Int J Breast Cancer. 2020 Apr 1;2020:8424365. doi: 10.1155/2020/8424365. eCollection 2020.
9
Epidermal growth factor receptor () gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort.马来西亚三阴性乳腺癌(TNBC)队列中表皮生长因子受体()基因改变与蛋白过表达
Onco Targets Ther. 2019 Sep 20;12:7749-7756. doi: 10.2147/OTT.S214611. eCollection 2019.
10
Metabolic role of fatty acid binding protein 7 in mediating triple-negative breast cancer cell death via PPAR-α signaling.脂肪酸结合蛋白 7 在通过 PPAR-α 信号介导三阴性乳腺癌细胞死亡中的代谢作用。
J Lipid Res. 2019 Nov;60(11):1807-1817. doi: 10.1194/jlr.M092379. Epub 2019 Sep 4.
人类表皮生长因子受体 2 基因扩增型乳腺癌中 17q12-q21 染色体基因扩增的定量及其临床相关性。
Breast Cancer Res. 2011 Feb 2;13(1):R15. doi: 10.1186/bcr2824.
4
MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups.MIB1/Ki-67 标记指数可将 2 级乳腺癌分为两个具有临床显著差异的亚组。
Breast Cancer Res Treat. 2011 Jun;127(3):591-9. doi: 10.1007/s10549-010-1028-3. Epub 2010 Jul 11.
5
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.新辅助顺铂在三阴性乳腺癌中的疗效。
J Clin Oncol. 2010 Mar 1;28(7):1145-53. doi: 10.1200/JCO.2009.22.4725. Epub 2010 Jan 25.
6
Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status.基于组织学分级和激素受体状态定义的乳腺癌亚型发病率的种族差异。
Cancer Causes Control. 2010 Mar;21(3):399-409. doi: 10.1007/s10552-009-9472-2. Epub 2009 Dec 19.
7
Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer.三阴性乳腺癌:临床病理特征与基底样乳腺癌的关系。
Mod Pathol. 2010 Jan;23(1):123-33. doi: 10.1038/modpathol.2009.145. Epub 2009 Oct 23.
8
Mutant p53 mediates survival of breast cancer cells.突变型p53介导乳腺癌细胞的存活。
Br J Cancer. 2009 Nov 3;101(9):1606-12. doi: 10.1038/sj.bjc.6605335. Epub 2009 Sep 22.
9
Clinical characteristics of triple-negative breast cancer: experience in an Asian developing country.三阴性乳腺癌的临床特征:一个亚洲发展中国家的经验
Asian Pac J Cancer Prev. 2009 Jul-Sep;10(3):395-8.
10
Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.日本乳腺癌学会登记委员会监测数据对三阴性乳腺癌的临床病理分析。
Breast Cancer. 2010 Apr;17(2):118-24. doi: 10.1007/s12282-009-0113-0. Epub 2009 May 23.